Heru reaches clinical milestone: 10,000 patient eyes examined with AR/VR platform

Article

With its portable capabilities, the Heru platform replaces legacy diagnostic devices and surpasses standard care in cost and size.

Heru reaches clinical milestone: 10,000 patient eyes examined with AR/VR platform


Heru Inc. announced its wearable vision diagnostic platform has screened 10,000 patient eyes since launching commercially in August 2021.

After more than a decade of clinical study, Heru, a cloud-based solution, originated at the University of Miami’s Bascom Palmer Eye Institute in partnership with researchers, scientists, and engineers, according to the company.

The platform provides real-time vision diagnoses with 6 vision diagnostic exams, and 5 reimbursable CPT medical billing codes in a single, wearable AR/VR headset. Practitioners can perform suprathreshold and full threshold visual fields, contrast sensitivity, color vision screening, and dark adaptations using the platform, according to a news release.

With its portable capabilities, the Heru platform replaces legacy diagnostic devices and surpasses standard care in cost and size.

The company’s most recent development is the Fast Pattern suprathreshold visual field test, which performs a patient diagnostic screening in 20 seconds and includes real-time clinical results.

“10,000 eyes screened is just the beginning,” said Corey Nielson, Heru’s Chief Customer Officer. “We accept the challenge of improving the way we diagnose vision disorders and will continue to develop our technology at a pace that cannot be met by traditional diagnostic devices.”

Recent Videos
Raman Bhakhri, OD, FAAO, details AAOpt 2024 talks
Dr. Jeffry Gerson, OD, FAAO, gave a presentation on diabetes at AAO 2024
Easy Anyama at Vision Expo West 2024
Brianna Rhue, OD, FAAO, FSLS, discusses AI and office technology at Vision Expo West
Spencer Johnson, OD, FAAO, overviews his talk on laser procedures at Optometry's Meeting
Raman Bhakhri, OD, FAAO, overviews his talk on medications' potential side effects on the retina with Optometry Times
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
© 2024 MJH Life Sciences

All rights reserved.